Key Highlights

● Regenlab USA filed an S-1 to list on Nasdaq under RGNA, without yet setting a share count or price range.

● The company makes platelet-rich plasma and hyaluronic acid devices across four therapeutic areas.

● Fiscal 2025 net product sales reached $49.2 million alongside a $1.2 million net loss and a going-concern disclosure.

● Chairman, President and CEO Antonino Turzi controls approximately 98.5% of voting power ahead of the IPO.

Regenlab USA, Inc. filed an S-1 registration statement on September 25, 2026 for a planned initial public offering, seeking to list on Nasdaq under the ticker RGNA (Proposed NASDAQ:RGNA). The company makes autologous cell-therapy medical devices, platelet-rich plasma and hyaluronic acid products, manufactured at facilities in New Jersey, France and Switzerland. The filing does not yet set a share count or price range for the offering.

The Products Behind The Business

Regenlab describes itself as providing standardized PRP, PRP-HA and tissue-engineering technologies across four therapeutic areas: musculoskeletal regeneration, advanced wound care, medical aesthetics and dermatology, and women's health and urogynecology. Its flagship RegenKit is a point-of-care platelet-rich plasma preparation system.

Cellular Matrix combines PRP with hyaluronic acid for moderate osteoarthritis, while RegenMatrix, still in the pipeline, pairs PRP with crosslinked HA for more advanced osteoarthritis. RegenWound is described in the filing as a gel-based autologous product currently reimbursed by CMS in the United States for chronic wound management, and SkinVisc is a hyaluronic-acid syringe for dermal revitalization.

Manufacturing Footprint And Financials

The company's Manufacturing operations span Jersey City, New Jersey; Paris, France; and Monthey, Switzerland, with a stated production capacity of six million tubes annually. For fiscal year 2025, Regenlab reported net product sales of $49.2 million and a net loss of $1.2 million. The filing also flags a Working Capital Deficit and includes a going-concern reference, meaning the company's auditors or management have raised doubt about its ability to continue operating without additional financing or improved cash flow, a disclosure investors should not overlook even alongside meaningful sales.

Ownership And Use Of Proceeds

Antonino Turzi, the company's Chairman, President and CEO, controls approximately 98.5% of voting power ahead of the IPO, a concentration the filing discloses directly. Giuseppe Calloni serves as CEO of the U.S. subsidiary. Regenlab says it intends to use IPO proceeds for sales and Marketing expansion, factory equipment, research and development, regulatory expenses, and working capital, a broad, standard set of uses rather than a specific capital project.

Risk Factors Disclosed In The Filing

The S-1 flags several risk categories investors should weigh: dependency on regulatory approvals for its medical devices, reimbursement challenges tied to insurance and government payer policies, competitive pressure in the regenerative-medicine space, a limited operating history for some product lines, and what the filing describes as substantial indebtedness. None of these are unusual for a medical-device IPO candidate, but they are explicitly disclosed rather than implied.

An IPO Filing, Not Yet A Priced Deal

Filing an S-1 is the first formal step toward a public offering, not a guarantee one will happen on any particular timeline or at any particular valuation. Regenlab's registration statement will typically go through one or more rounds of SEC comments and amendments, during which the company may add or revise financial statements, update risk factors, or adjust the structure of the deal, before the SEC declares it effective and underwriters can begin marketing shares to investors. The filing reviewed here does not name underwriters, nor does it specify a target date for pricing or listing.

Items To Track As The Registration Advances

Share count and price range are not yet set; a future amendment will need to specify offering terms before pricing. The going-concern and working-capital-deficit disclosures bear watching in subsequent amendments or the eventual prospectus. RegenMatrix remains in the pipeline rather than a commercialized product, per the filing. Antonino Turzi's roughly 98.5% pre-IPO voting control means public shareholders would hold limited influence over corporate decisions even after listing.